Most Read Articles
6 days ago
A strong belief in the necessity of medication is associated with better adherence to oral disease-modifying antirheumatic drugs (DMARDs) or prednisone, while higher self-efficacy correlates with poor adherence, in a diverse cohort of patients with rheumatoid arthritis (RA), suggests a study.
5 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
3 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 5 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.

Longer lactation duration cuts NAFLD risk in moms

10 Nov 2018

A longer duration of lactation appears to lower the risk of developing nonalcoholic fatty liver disease (NAFLD), according to a recent US study.

The study included 844 mothers (median age at baseline 25 years) who gave birth from 1985–1986 and who underwent computed tomography quantification of hepatic steatosis 25 years after. Multivariable logistic regression analyses were performed to evaluate the relationship between NAFLD diagnosis and lactation duration.

Based on self-reported information, participants were categorized into three according to the duration of lactation: 0–1 month (n=276), >1–6 months (n=209) and >6 months (n=359). On the other hand, 54 women were positive for NAFLD at follow-up.

NAFLD rates dropped with increasing lactation duration. In mothers who breastfed for 0–1 month, the corresponding disease prevalence was 8.3 percent, which decreased to 7.7 percent and 4.2 percent for those with >1–6 months and >6 months of lactation, respectively.

Moreover, those who breastfed for >6 months were significantly less likely to developed NAFLD than those with lactation duration of 0–1 month (adjusted odds ratio [OR], 0.46; 95 percent CI, 0.22–0.97; p=0.04). A significant downward linear trend was observed across all duration categories (p=0.04), but no such protective effect was seen in women who breastfed for >1–6 months (adjusted OR, 0.84; 0.42–1.70; p=0.64).

Any breastfeeding was likewise unrelated to a lower risk of NAFLD, further providing support that there is a threshold effect of lactation durations >6 months.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
A strong belief in the necessity of medication is associated with better adherence to oral disease-modifying antirheumatic drugs (DMARDs) or prednisone, while higher self-efficacy correlates with poor adherence, in a diverse cohort of patients with rheumatoid arthritis (RA), suggests a study.
5 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
3 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 5 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.